Identifying Barriers To Implementing Guidelines For Monitoring Metabolic Syndrome In Patients Prescribed Second-Generation Antipsychotics In Incarcerated Populations
Individuals with serious mental illness (SMI) have increased rates of cardiovascular disease (CVD) and mortality. Also, the evidence indicates that second-generation antipsychotics (SGAs, a conventional treatment) increase the risk of metabolic syndrome (MetS) often leading to weight gain, cardiovascular disease (CVD) and type 2 diabetes (DM 2). U. S. correctional institutions, faced with increased rates of mental illness in its population, are confronted with the need to assure adequate monitoring for its patients treated with SGAs. This paper reviews guidelines for monitoring incarcerated patients to ensure early intervention that can improve clinical outcomes. Characteristics of the incarcerated population and institution-related barriers to implementing guidelines are identified along with strategies for improved monitoring and issues for further study.
barriers to care, mental illness in U. S. jails and prisons, metabolic syndrome, Second generation antipsychotics
Networked Digital Library of Theses and Dissertations